Does Gilenya Increase Shingles Risk?
Gilenya (fingolimod) raises the risk of herpes zoster infections, including shingles, by suppressing parts of the immune system that fight viruses like varicella-zoster, which causes chickenpox and later shingles.[1][2] Clinical trials showed 3% of Gilenya patients developed herpes zoster versus 1% on placebo, with higher rates in those previously exposed to chickenpox.[1] Post-marketing data confirms this as a known risk, especially in the first year of treatment.[2]
How Common Is Shingles on Gilenya?
Shingles occurs in about 2-4% of patients annually on Gilenya, per real-world studies and FDA reports—roughly double the general population rate for adults over 50 (around 1%).[2][3] Risk factors include age over 50, prior immunosuppression, and not having chickenpox immunity. It's often mild but can lead to complications like postherpetic neuralgia.[1]
Why Does This Happen?
Gilenya traps lymphocytes in lymph nodes, reducing their circulation to fight infections. This impairs T-cell responses needed to control latent varicella-zoster virus reactivation, mimicking effects seen with other immunosuppressants like JAK inhibitors.[2][4]
What Should Patients Do Before Starting?
Doctors screen for varicella-zoster antibodies; unexposed patients get the chickenpox vaccine at least 4 weeks before Gilenya to cut shingles risk by over 80%.[1][5] The Shingrix vaccine is also recommended for adults 50+ on immunosuppressants, ideally 2-4 weeks prior.[5]
Symptoms to Watch For
Early shingles signs include painful rash, blisters, fever, or headache, typically on one side of the body. Report immediately—antivirals like valacyclovir work best within 72 hours.[1][2]
Compared to Other MS Drugs
Gilenya's shingles risk (2-4%) is moderate: lower than ocrelizumab (4-6%) or cladribine (up to 5%), but higher than interferons (<1%). Tecfidera has minimal impact.[3][4]
Treatment and Prevention Tips
If shingles develops, start antivirals promptly; severe cases may need hospitalization. Long-term, monitor with regular blood tests and consider pausing Gilenya during outbreaks.[2] No Gilenya-specific patents tie to shingles risk; generic fingolimod enters post-2027 U.S. exclusivity end.[6]
[1] Gilenya Prescribing Information, Novartis (FDA label, updated 2023). https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/022527s020lbl.pdf
[2] EMA Gilenya Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/gilenya-epar-product-informationen.pdf
[3] Lancet Neurology study on MS therapies and zoster (2021). https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00192-5/fulltext
[4] CDC Immunosuppressants and Zoster Guidelines. https://www.cdc.gov/shingles/hcp/vaccine-considerations/immunosuppressed-adults.html
[5] ACIP Recommendations for Shingrix in Immunocompromised. https://www.cdc.gov/vaccines/acip/recs/grade/shingles-shingrix.html
[6] DrugPatentWatch: Fingolimod Patents. https://www.drugpatentwatch.com/p/tradename/GILENYA